EXHIBIT 10.7

* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                               AMENDMENT EIGHT TO
                              DEVELOPMENT AGREEMENT
                    TESTING OF SOLVENT LEVELS IN PLASMA BAGS

         This Amendment Eight made as of February 13, 2002 ("Effective Date")
between SRI International, a California, non-profit and public benefit
corporation, having a place of business located at 333 Ravenswood Avenue, Menlo
Park, CA 94025 (hereinafter "SRI") and Lipid Sciences Incorporated, an Arizona
corporation, having a place of business located at 7068 Koll Center Parkway,
Suite 401, Pleasanton, CA 94566 (hereinafter "LSI").

         WHEREAS, SRI and LSI have entered into a development agreement having
an effective date of October 6, 2000 and an Amendment One thereto dated March 8,
2001 and Amendment Two dated March 28, 2001; Amendment Three dated May 12, 2001;
Amendment Four dated May 13, 2001, Amendment Five dated May 13, 2001, Amendment
Six dated December 5, 2001 and Amendment Seven dated October 6, 2000,
(hereinafter individually and collectively "Development Agreement") and which
the parties hereby amend; and

         WHEREAS, the parties intend that this Amendment Eight provide for the
details of additional work related to the testing needed to incubate saline in
various plasma storage bags with varying levels of solvent, which is outside of
the scope of Phase II Development Plan of the Development Agreement.

         NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

         1.       For consistency and unless otherwise defined herein all
                  initially capitalized terms shall have the meaning set forth
                  in the Development Agreement.

         2.       The scope of work and project cost, which the parties agree
                  are outside of the scope of Phase 11 Development Plan of the
                  Development Agreement are attached hereto as Exhibit A.

         3.       Unless expressly amended by this Amendment Seven, all other
                  terms and conditions of the Development Agreement shall remain
                  in full force and effect.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.


   SRI:                              LSI:
   SRI International                 Lipid Sciences, Incorporated
   By:  /s/ V. Rene Harmount         By: /s/ Phil Radlick
       --------------------------        ---------------------
       V. Rene Harmount                  Phil Radlick, Ph.D.
       Group Manager, Contracts          President & Chief Executive Officer




                                    EXHIBIT A

                                     [ * ]


                                       2